Form 4: GUIDED THERAPEUTICS Director John Imhoff Granted 110,000 Stock Options

John E. Imhoff, a Director of Guided Therapeutics Inc., was granted 110,000 stock options with an exercise price of $0.14, vesting over time until June 2028.

Summary

• John E. Imhoff, a Director of Guided Therapeutics Inc. (GTHP), acquired 110,000 stock options.
• The options have an exercise price of $0.14 per share.
• The grant date for these options was June 3, 2025.
• One-fourth (27,500 shares) of the shares subject to the award vested immediately on June 3, 2025.
• The remaining shares will vest monthly, commencing September 3, 2025, and will be fully vested by June 2, 2028, contingent on Mr. Imhoff's continued service.
• The options expire on June 2, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and a commitment to long-term value creation. It's a standard compensation practice, so not overwhelmingly positive, but certainly not negative.

Positives

• The granting of stock options to a director aligns management's interests with shareholders, incentivizing long-term performance and value creation.
• The structured vesting schedule encourages continued service and commitment from the director, promoting stability in governance.

Risks

• The value of the stock options is directly dependent on the future market price of Guided Therapeutics Inc. common stock exceeding the exercise price of $0.14.
• If the company's stock price does not appreciate above the exercise price, the options may not be exercised, potentially rendering them worthless at expiration.

Future Outlook

The granting of long-term stock options to a director suggests an expectation of future value creation and continued service from key personnel, aligning their incentives with the company's long-term performance and strategic objectives.

Industry Context

This transaction represents a common form of executive and director compensation within the biotechnology and medical device industry. Equity grants are widely used to retain talent and align their interests with shareholder value creation, particularly in a sector characterized by significant research and development investments, long product development cycles, and complex regulatory environments.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard practice for compensating directors in publicly traded companies, especially in growth-oriented sectors like medical technology.
• The exercise price of $0.14, if it represents the market price at the time of grant, is typical for 'at-the-money' options, which are common for compensation.
• The 3-year vesting period (from grant to full vesting) and 10-year expiration period are within common industry ranges for such equity awards, balancing retention with long-term incentive.

Stakeholder Impact

• **Shareholders:** The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases, incentivizing performance.
• **Employees:** While not directly impacting employees, this compensation event reflects the company's approach to incentivizing key personnel, which can indirectly influence overall compensation philosophy and morale.

Next Steps

• Continued service of John E. Imhoff as a Director of Guided Therapeutics Inc. for the options to fully vest according to the schedule.
• Potential exercise of vested stock options by Mr. Imhoff if the company's stock price exceeds the exercise price of $0.14, indicating a positive return for the director and potentially for shareholders.

Key Dates

Recommendation

Keywords

GUIDED THERAPEUTICS INC, GTHP, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership